Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

How Reliable Is PD-L1 Expression as a Predictor of Immune Response?

November 9th 2017

There is a great need—and opportunity—to improve ovarian cancer outcomes by understanding the immune milieu of ovarian cancers and harnessing the power of immunotherapy.

Dr. Sabbatini on the Future of Dose-Dense Therapy in Ovarian Cancer

November 9th 2017

Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses the future of dose-dense therapy in ovarian cancer.

Final Results Confirm OS Benefit Associated with Olaparib in Relapsed Platinum-Sensitive Serous Ovarian Cancer

November 9th 2017

Maintenance therapy with olaparib monotherapy provides clinically significant, long-term treatment benefits and is safe in patients with platinum-sensitive relapsed serous ovarian cancer.

Dr. Sessa Discusses ATR Inhibitors in BRCA-Mutated Tumors

November 8th 2017

Cristiana Sessa, MD, head of Phase I-II Unit and Pharmacology, vice head of Medical Oncology and Head of Clinical Research, Oncology Institute of Southern Switzerland, discusses ataxia–telangiectasia and Rad3 related (ATR) inhibitors in patients with ovarian cancer who have BRCA-mutated tumors.

Dr. Ledermann on the Results of the ARIEL3 Trial in Ovarian Cancer

November 8th 2017

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses the results of the ARIEL3 trial in ovarian cancer.

Expert Discusses Rucaparib Maintenance in Ovarian Cancer

November 8th 2017

Jonathan Ledermann, MD, discussed these results, as well as the future of PARP inhibitors in the maintenance setting for patients with ovarian cancer.

Survey Shows Patients Consider Several Factors of Maintenance Therapy for Ovarian Cancer Treatment

November 8th 2017

Patients with ovarian cancer were unified in their responses regardless of age, disease stage, or whether they had primary or recurrent disease, and were more likely to opt to receive maintenance therapy if it could offer delay of disease progression and allow patients to maintain or improve their quality of life.

PALB2 Mutation Implicated in Higher Risk of Breast Cancer, Not Ovarian

November 8th 2017

Deleterious mutations in the PALB2 gene may account for the development of breast cancer in women with an elevated risk due to a family history of breast or ovarian cancer, but who test negative for the BRCA1 or BRCA2 genes.

Dr. Leitao on the Role of Surgery in Ovarian Cancer

November 8th 2017

Mario M. Leitao Jr, MD, FACOG, FACS, fellowship director, gynecology service, director, Minimal Access and Robotic Surgery Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses the role of surgery for patients with ovarian cancer.

Maintenance Rucaparib Extended PFS in Women with Platinum-Sensitive Recurrent Ovarian Cancer

November 8th 2017

Rucaparib delayed disease recurrence in the intent to treat population and across subgroups of women with ovarian cancer.

Secondary Cytoreductive Surgery Shows Promise in Ovarian Cancer

November 8th 2017

Jalid Sehouli, MD, PhD, discusses the significance of these findings in the treatment of patients with platinum-sensitive recurrent ovarian cancer.

No Overall Survival Advantage in Frontline Nintedanib With Chemotherapy in Advanced Ovarian Cancer

November 7th 2017

The final analysis of overall survival data from the phase III AGO-OVAR 12 trial of nintedanib plus carboplatin/paclitaxel versus carboplatin/paclitaxel alone in women with chemotherapy-naive advanced ovarian cancer did not demonstrate a survival advantage with the addition of nintedanib.

Salvage Surgery Improved PFS in Platinum-Sensitive Recurrent Ovarian Cancer

November 7th 2017

Patients with relapsed ovarian cancer and a positive Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) score experienced prolonged progression-free survival after undergoing a second cytoreductive surgery followed by platinum-based chemotherapy.

Dr. Sehouli Discusses Trial of Secondary Cytoreductive Surgery in Ovarian Cancer

November 7th 2017

Jalid Sehouli, MD, professor, director of the Clinic Campus Virchow and Campus Benjamin Franklin Charité Center Gynecology, Charité – Universitatsmedizin Berlin, discusses a trial of secondary cytoreductive surgery in patients with ovarian cancer, presented at the 2017 International Meeting of the European Society of Gynaecological Oncology (ESGO).

Mixed Findings Show Dose-Dense Therapy Noninferior to IP Treatment in Ovarian Cancer

November 6th 2017

Paul Sabbatini, MD, discusses the recent data surrounding IP and dose-dense therapy and the next steps for both treatment approaches in ovarian cancer.

Robotic Laparoscopy Improves Outcomes for Patients With Ovarian Cancer, Reaffirms Role of Surgery

November 6th 2017

Mario M. Leitao, Jr, MD, FACOG, FACS, discusses how surgery retains its imperative role in ovarian cancer and sheds light on the challenges that still remain.

Clinical Impact of Chronic Low-Grade Nausea Is Woefully Underestimated

November 1st 2017

Antineoplastic drug therapy has been delivered by the oral route since the earliest days of the modern chemotherapeutic era.

Dr. Pothuri on PARP Inhibitors for Ovarian Cancer

October 30th 2017

Bhavana Pothuri, MD, an associate professor in the Department of Obstetrics and Gynecology at NYU Langone's Perlmutter Cancer Center, discusses PARP inhibitors for the treatment of patients with ovarian cancer.

FDA Accepts sBLA for Bevacizumab in First-Line Ovarian Cancer

October 27th 2017

The FDA has accepted a supplemental biologics license application for bevacizumab (Avastin) for the first-line treatment of advanced ovarian cancer.

FDA Approval Sought for Maintenance Rucaparib in Ovarian Cancer

October 10th 2017

A supplemental new drug application has been submitted to the FDA for rucaparib as maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.